Intensive TMS for Bipolar Depression

Sponsor
University of Pennsylvania (Other)
Overall Status
Recruiting
CT.gov ID
NCT05228457
Collaborator
(none)
32
1
2
11.1
2.9

Study Details

Study Description

Brief Summary

The research study is being conducted to test whether using high dose spaced theta-burst rTMS (a form of transcranial magnetic stimulation) produces a significant reduction in depressive symptoms compared with sham. This project will recruit patients aged 18-70 with symptoms of bipolar depression who have failed (or not shown signs of improvement) after at least two prior treatments.

Condition or Disease Intervention/Treatment Phase
  • Device: Intensive intermittent theta-burst stimulation (iTBS)
N/A

Detailed Description

The research study is being conducted to test whether using high dose spaced theta-burst rTMS (a form of transcranial magnetic stimulation) produces a significant reduction in depressive symptoms compared with sham. This project will recruit patients aged 18-70 with symptoms of bipolar depression who have failed (or not shown signs of improvement) after at least two prior treatments. The null hypothesis is that there will be no difference in reductions in depressive symptoms by the end of a five-day treatment period. The alternative hypothesis is that, compared with sham, active TMS will result in a greater reduction in depressive symptoms by the end of the treatment period. Participants will be randomly assigned to active or sham conditions: 50% to active and 50% to sham.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
32 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Triple (Participant, Investigator, Outcomes Assessor)
Primary Purpose:
Other
Official Title:
Intensive TMS for Rapid Relief of Bipolar Depression Symptoms
Actual Study Start Date :
Mar 1, 2022
Anticipated Primary Completion Date :
Feb 1, 2023
Anticipated Study Completion Date :
Feb 1, 2023

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: Active Transcranial Magnetic Stimulation

Active Intensive iTBS involves intermittent theta-burst stimulation (iTBS), a patterned form of repetitive transcranial magnetic stimulation (rTMS) over the left dorsal lateral prefrontal cortex (L-DLPFC).

Device: Intensive intermittent theta-burst stimulation (iTBS)
Intensive iTBS is intermittent theta-burst stimulation (iTBS), a patterned form of repetitive transcranial magnetic stimulation (rTMS) over a specific brain region.

Sham Comparator: Sham Transcranial Magnetic Stimulation

Sham Intensive iTBS involves using the coil's electric stimulation functionality that allows for the delivery of a brief electric pulse to the scalp simultaneous to the TMS pulse, which mimics the scalp sensation from active stimulation.

Device: Intensive intermittent theta-burst stimulation (iTBS)
Intensive iTBS is intermittent theta-burst stimulation (iTBS), a patterned form of repetitive transcranial magnetic stimulation (rTMS) over a specific brain region.

Outcome Measures

Primary Outcome Measures

  1. Clinical efficacy of high dose spaced theta burst (HDS-TBS) [Through study completion, approximately 1 week]

    The primary outcome will be based on the set of repeated Montgomery Asberg Depression scores (10 items rated on a 0-6 scale, 0-60 possible score range, with higher scores indicating greater depressive symptomology), obtained at baseline and on each of the five treatment days.

Secondary Outcome Measures

  1. Relationship between change in brain resting state functional connectivity and treatment effects [Upon study completion, approximately 1 week]

    The main secondary outcome will be the change in correlation of the dorsal lateral prefrontal cortex (DLPFC) with limbic regions, as gathered during baseline and post stimulation MRI scans.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 70 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Bipolar depression (BP I and BP II) by Diagnostic and Statistical Manual 5 (DSM 5) criteria

  • Age 18-70

  • Right or left handed

  • All genders

  • Treatment resistant depression, as in they must have treatment resistant depression with 2 or more prior antidepressant trials that have failed to produce a response (> 50% reduction in symptoms) using ATHF criteria

  • Able to provide informed consent to participate in the study

  • Must be on a stable medication regimen, requiring at least one mood stabilizer

  • Depression severity as represented by scoring at least 20 on Montgomery-Asberg Depression Rating Scale (MADRS)

Exclusion Criteria:
  • No current substance abuse disorder for the past 6 months (previous substance abuse not exclusionary)

  • Any psychotic disorder or current active psychotic symptoms (personality disorders not exclusionary unless in the opinion of the referring psychiatrist it would jeopardize participation)

  • No dementia or other major neurological disorders

  • Not having depression as primary disorder

  • No major medical illness, for example metastatic cancer, end stage renal disease

  • Not able to verify contact information. Participants must be able to follow through with the study & must have verified contact information and at least one verified contact

  • Pregnancy. While there are no known risks to a fetus this is a new use of TMS, which has not been tested, thus pregnancy is exclusionary

  • Score on Young Mania Rating Scale (YMRS) greater than 12 (patients with mixed features have been shown not to respond well to TMS treatment)

  • Rapid cycling Bipolar illness (patients with > 4 mood episodes within the past year will be excluded, as they have a higher risk of switch to mania)

Contacts and Locations

Locations

Site City State Country Postal Code
1 Center for Neuromodulation in Depression and Stress, University of Pennsylvania Philadelphia Pennsylvania United States 19104

Sponsors and Collaborators

  • University of Pennsylvania

Investigators

  • Principal Investigator: Yvette Sheline, MD, Perelman School of Medicine University of Pennsylvania

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Yvette Sheline, McLure Professor of Radiology, Neurology and Psychiatry, University of Pennsylvania
ClinicalTrials.gov Identifier:
NCT05228457
Other Study ID Numbers:
  • 850359
First Posted:
Feb 8, 2022
Last Update Posted:
Mar 18, 2022
Last Verified:
Mar 1, 2022
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
Yes
Additional relevant MeSH terms:

Study Results

No Results Posted as of Mar 18, 2022